- Home
- PYPD vs PIII Comparison
PYPD vs PIII Comparison
Compare PYPD & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- PIII
- Stock Information
- Founded
- PYPD 2008
- PIII 2015
- Country
- PYPD Israel
- PIII United States
- Employees
- PYPD N/A
- PIII N/A
- Industry
- PYPD Medical/Dental Instruments
- PIII Medical/Nursing Services
- Sector
- PYPD Health Care
- PIII Health Care
- Exchange
- PYPD Nasdaq
- PIII Nasdaq
- Market Cap
- PYPD 30.1M
- PIII 30.8M
- IPO Year
- PYPD 2020
- PIII N/A
- Fundamental
- Price
- PYPD $2.75
- PIII $0.18
- Analyst Decision
- PYPD Strong Buy
- PIII Hold
- Analyst Count
- PYPD 2
- PIII 2
- Target Price
- PYPD $10.50
- PIII $0.25
- AVG Volume (30 Days)
- PYPD 13.1K
- PIII 721.1K
- Earning Date
- PYPD 05-07-2025
- PIII 03-27-2025
- Dividend Yield
- PYPD N/A
- PIII N/A
- EPS Growth
- PYPD N/A
- PIII N/A
- EPS
- PYPD N/A
- PIII N/A
- Revenue
- PYPD N/A
- PIII $1,500,455,000.00
- Revenue This Year
- PYPD N/A
- PIII $21.45
- Revenue Next Year
- PYPD N/A
- PIII N/A
- P/E Ratio
- PYPD N/A
- PIII N/A
- Revenue Growth
- PYPD N/A
- PIII 18.48
- 52 Week Low
- PYPD $2.37
- PIII $0.15
- 52 Week High
- PYPD $5.09
- PIII $1.02
- Technical
- Relative Strength Index (RSI)
- PYPD 42.15
- PIII 45.80
- Support Level
- PYPD $2.66
- PIII $0.16
- Resistance Level
- PYPD $2.97
- PIII $0.20
- Average True Range (ATR)
- PYPD 0.14
- PIII 0.02
- MACD
- PYPD -0.02
- PIII 0.00
- Stochastic Oscillator
- PYPD 8.86
- PIII 49.57
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.